c: Hematology laboratories include hemoglobin, hematocrit, white blood cell count with differential (including absolute eosinoph il count), and platelets. In addition, PT/INR and APTT should be checked as clinically indicated. d: Chemistry laboratories inclu de sodium, potassium, chloride, bicarbonate, urea nitrogen, creatinine, glucose, calcium, albumin, total protein, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase. e: Serum PSA should be obtained pre -treatm ent and on the day of surgery, and as clinically indicated thereafter according to institutional practices. f: At baseline (day 1) , collect 10 mL of blood into a 10 -mL ACD (acid citrate dextrose) tube [test code 4470; CPT code 86813]. g: Blood sample s will be co llected at day 1 and again on the day of prostatectomy and at follow up visit. At each time point, 2 plain (red top) or SST (gold top) tubes should be collected, each containing ≥5mL of blood. After centrifugation, serum should be transferred into plastic cryovials and frozen at – 20°C or colder until the time of analysis (see Section 5.4 ). h: Peripheral blood lymphocytes (PBLs) w ill be obtained by collecting 200 mL of blood into 50 -mL he parinized conical tube s. PBLs will be prepared by Ficoll -Hypaque density gradient centrifugation according to standard protocols, and will be cryopreserved in a liquid nitrogen freezer at – 140°C for further batched analyses. i: Harvested prostate gland to be evaluated for CD8 + T cell infiltration, as well as other secondary endpoints. j: Archival prostate core biopsies to be centrally reviewed at baseline prior to study entry; radical prostatectomy specimens to be processed at Johns Hopkins according to standard procedures. k: The post -operative evaluation (28 days after prostatectomy) m ay take place over the telephone or in person, but patients are required to have hematology and chemistry labs collected at this time -point for safety purposes. l: In addition, PSA should be measured every 3 (±1) months in the first year after prostatectomy, and every 6 (±2) months in the second and third years after prostatectomy. Androgen suppression with prostate GVAX and cyclophosphamide J1265 Johns Hopkins University 26 of 68 J1265 PROT (Vers) 1.4 113012 5.2 Screening/Pretreatment Evaluation Before initiating any screening activities, the scope of the study should be explained to each patient. Patients should be advised of any kn own risks inherent in the planned procedures, any alternative treatment options, their right to withdraw from the study at any time and for any reason, and their right to privacy.